Search Results for "Drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug. Results 2561 to 2570 of 2581 total matches.
Prothrombin Complex Concentrates to Reverse Warfarin-Related Bleeding
The Medical Letter on Drugs and Therapeutics • Oct 03, 2011 (Issue 1374)
Letter®
On Drugs and Therapeutics
Volume 53 (Issue 1374)
October 3, 2011
www.medicalletter.org ...
Warfarin-related bleeding, especially intracranial hemorrhage,
can be catastrophic. Several products are available
to reverse warfarin’s anticoagulant effect.
COVID-19 Update: FDA Authorizes Novavax COVID-19 Vaccine
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022 (Issue 1656)
, and dosing recommendations. Available at:
www.medicalletter.org/drugs-for-covid-19.
Additional COVID-19 ...
The FDA has issued an Emergency Use Authorization
(EUA) for an adjuvanted protein subunit COVID-19
vaccine manufactured by Novavax. The vaccine
is indicated for use as a two-dose primary series
to prevent COVID-19 in adults; it is not authorized
for use in children or as a booster dose. Three
other COVID-19 vaccines are available in the US for
primary immunization of adults; the mRNA vaccines
manufactured by Pfizer/BioNTech (Comirnaty) and
Moderna (Spikevax) are FDA-licensed for this indication,
and the adenovirus-based vaccine manufactured
by Johnson & Johnson (Janssen) is...
Eflapegrastim (Rolvedon) for Prevention of Chemotherapy-Induced Febrile Neutropenia
The Medical Letter on Drugs and Therapeutics • May 29, 2023 (Issue 1677)
by First
Databank, Inc. All rights reserved. ©2023. www.fdbhealth.
com/drug-pricing-policy.
DOSAGE ...
Eflapegrastim-xnst ((Rolvedon) [Spectrum]; previously
called Rolontis), a granulocyte colony-stimulating
factor (G-CSF) conjugated to an Fc fragment of human
IgG4, has been approved by the FDA to decrease
the incidence of infection, as manifested by febrile
neutropenia, in adults with nonmyeloid malignancies
receiving myelosuppressive chemotherapy that can
cause clinically significant febrile neutropenia.
Med Lett Drugs Ther. 2023 May 29;65(1677):83-4 doi:10.58347/tml.2023.1677b | Show Introduction Hide Introduction
Corneal Surgery for Myopia
The Medical Letter on Drugs and Therapeutics • Oct 15, 1993 (Issue 907)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Readers have inquired about the effectiveness and safety of operations on the cornea to correct refractive errors and restore normal vision without glasses or contact lenses. Several different operations are now being used for this purpose.
Glucagon Nasal Powder (Baqsimi) for Severe Hypoglycemia
The Medical Letter on Drugs and Therapeutics • Sep 23, 2019 (Issue 1581)
catecholamine release from the tumor) or
an insulinoma.
DRUG INTERACTIONS – Patients taking the NSAID ...
The FDA has approved glucagon nasal powder
(Baqsimi – Lilly) for treatment of severe hypoglycemia
in patients ≥4 years old with diabetes. Baqsimi is the
first noninjectable glucagon formulation to become
available in the US. Injectable glucagon emergency kits
(GlucaGen Hypokit, and generic) have been available
for years, but they require reconstitution of the
lyophilized powder by the caregiver immediately before
injection. An injectable glucagon formulation that does
not require reconstitution was recently approved by the
FDA (Gvoke) and is expected to become available...
Corticosteroids in Community-Acquired Pneumonia
The Medical Letter on Drugs and Therapeutics • Jan 13, 2020 (Issue 1589)
to a lower rate of late
radiographic progression with methylprednisolone
(2% vs 15%); the drug did ...
Recently updated guidelines from the American
Thoracic Society (ATS) and the Infectious Diseases
Society of America (IDSA) address the use of
corticosteroids as an adjunct to antimicrobials for
treatment of community-acquired pneumonia (CAP).
FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021 (Issue 1615)
that persons with a history of anaphylaxis to a vaccine,
drug, or food not receive the Pfizer-BioNTech vaccine ...
The FDA has issued an Emergency Use Authorization
(EUA) for the Pfizer-BioNTech mRNA-based vaccine
for prevention of COVID-19 in persons ≥16 years old.
COVID-19 Update: New Novavax Vaccine Formulation for 2023-2024
The Medical Letter on Drugs and Therapeutics • Nov 13, 2023 (Issue 1689)
formulations for 2023-2024. Med Lett Drugs Ther 2023;
65:167.
3. F Dubovsky. Data in support of Novavax XBB ...
A new 2023-2024 formulation of the adjuvanted
protein subunit COVID-19 vaccine manufactured by
Novavax that was developed to more closely target
currently circulating SARS-CoV-2 variants has been
made available in the US under an FDA Emergency Use Authorization (EUA) for use in persons ≥12
years old. The original formulation of the Novavax
vaccine is no longer authorized for use in the US.
In September, updated formulations of the mRNA
COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) were
licensed by the FDA for use in persons ≥12 years old
and...
Med Lett Drugs Ther. 2023 Nov 13;65(1689):182-3 doi:10.58347/tml.2023.1689b | Show Introduction Hide Introduction
Corneal Surgery for Correction of Refractive Errors
The Medical Letter on Drugs and Therapeutics • Dec 17, 1999 (Issue 1068)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
All refractive corneal surgery reshapes the cornea to redirect light rays so that they focus on the retine....
Tattoo Removal
The Medical Letter on Drugs and Therapeutics • Nov 24, 2003 (Issue 1170)
95
The Medical Letter
®
On Drugs and Therapeutics
www.medicalletter.org
Published ...
While more people than ever are getting tattoos, many come to regret their decision and would like to have them removed. The technology of removing tattoos is much better than it used to be, but still far from perfect. Complete removal of all pigments with restoration of normal skin color and texture is not always possible (M Kuperman-Beade et al, Am J Clin Dermatol 2001; 2:21; GM Lipper and RR Anderson in IM Freedberg et al, eds, Fitzpatrick's Dermatology in General Medicine 6th ed, New York:McGraw-Hill 2003, page 2508).